Stock Scorecard
Stock Summary for Lyell Immunopharma Inc (LYEL) - $22.72 as of 11/24/2025 9:07:18 PM EST
Total Score
9 out of 30
Safety Score
30 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LYEL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LYEL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LYEL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LYEL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LYEL (30 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 3 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for LYEL
Financial Details for LYEL
Company Overview |
|
|---|---|
| Ticker | LYEL |
| Company Name | Lyell Immunopharma Inc |
| Country | USA |
| Description | Lyell Immunopharma, Inc. is a cutting-edge biopharmaceutical company headquartered in South San Francisco, California, with additional facilities in Seattle and Bothell, Washington. The company specializes in pioneering T-cell reprogramming technologies designed to formulate innovative therapies targeting solid tumors, thereby enhancing the effectiveness and longevity of T-cell treatments. With its proprietary platforms and a strong commitment to meeting significant unmet medical needs in oncology, Lyell is well-positioned to transform cancer treatment and play a critical role in the evolving immuno-oncology sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 22.72 |
| Price 4 Years Ago | 154.80 |
| Last Day Price Updated | 11/24/2025 9:07:18 PM EST |
| Last Day Volume | 92,749 |
| Average Daily Volume | 30,335 |
| 52-Week High | 20.80 |
| 52-Week Low | 7.65 |
| Last Price to 52 Week Low | 196.99% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.52 |
| Sector PE | 86.12 |
| 5-Year Average PE | -45.09 |
| Free Cash Flow Ratio | 3.90 |
| Industry Free Cash Flow Ratio | 13.25 |
| Sector Free Cash Flow Ratio | 27.29 |
| Current Ratio Most Recent Quarter | 10.30 |
| Total Cash Per Share | 5.82 |
| Book Value Per Share Most Recent Quarter | 17.06 |
| Price to Book Ratio | 1.11 |
| Industry Price to Book Ratio | 34.10 |
| Sector Price to Book Ratio | 33.20 |
| Price to Sales Ratio Twelve Trailing Months | 9,020.33 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.80 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 21,218,200 |
| Market Capitalization | 482,077,504 |
| Institutional Ownership | 50.16% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -46.18% |
| Reported EPS 12 Trailing Months | -22.75 |
| Reported EPS Past Year | -5.20 |
| Reported EPS Prior Year | -1.05 |
| Net Income Twelve Trailing Months | -325,660,000 |
| Net Income Past Year | -342,994,000 |
| Net Income Prior Year | -234,632,000 |
| Quarterly Revenue Growth YOY | -55.90% |
| 5-Year Revenue Growth | -37.83% |
| Operating Margin Twelve Trailing Months | -248,353.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 123,575,000 |
| Total Cash Past Year | 105,597,000 |
| Total Cash Prior Year | 145,647,000 |
| Net Cash Position Most Recent Quarter | 123,575,000 |
| Net Cash Position Past Year | 105,597,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 382,824,000 |
| Total Stockholder Equity Prior Year | 654,952,000 |
| Total Stockholder Equity Most Recent Quarter | 329,121,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -165,535,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -7.80 |
| Free Cash Flow Past Year | -162,858,000 |
| Free Cash Flow Prior Year | -166,380,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.34 |
| MACD Signal | 0.35 |
| 20-Day Bollinger Lower Band | 7.74 |
| 20-Day Bollinger Middle Band | 13.68 |
| 20-Day Bollinger Upper Band | 19.63 |
| Beta | -0.07 |
| RSI | 54.30 |
| 50-Day SMA | 12.05 |
| 150-Day SMA | 32.14 |
| 200-Day SMA | 52.23 |
System |
|
| Modified | 11/22/2025 3:19:03 AM EST |